• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.

作者信息

Zhao Binghao, Ma Wenbin

机构信息

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; China Pituitary Disease Registry Center, Chinese Pituitary Adenoma Cooperative Group, Beijing, People's Republic of China; China Alliance of Rare Diseases, Beijing, People's Republic of China.

出版信息

J Thorac Oncol. 2022 Sep;17(9):e85-e86. doi: 10.1016/j.jtho.2022.01.020.

DOI:10.1016/j.jtho.2022.01.020
PMID:36031298
Abstract
摘要

相似文献

1
Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.劳拉替尼持续使用可能为ALK阳性非小细胞肺癌带来疾病进展后的益处；更多因素应予以考虑。
J Thorac Oncol. 2022 Sep;17(9):e85-e86. doi: 10.1016/j.jtho.2022.01.020.
2
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.ALK 阳性 NSCLC 疾病进展后继续使用洛拉替尼治疗。
J Thorac Oncol. 2022 Apr;17(4):568-577. doi: 10.1016/j.jtho.2021.12.011. Epub 2022 Jan 10.
3
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.洛拉替尼用于治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌：IFCT-1803 LORLATU队列研究结果
Eur J Cancer. 2022 May;166:51-59. doi: 10.1016/j.ejca.2022.01.018. Epub 2022 Mar 9.
4
[New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer].[新药获批：一线劳拉替尼用于晚期ALK阳性非小细胞肺癌]
Bull Cancer. 2022 Sep;109(9):877-878. doi: 10.1016/j.bulcan.2022.04.006. Epub 2022 Jun 15.
5
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.洛拉替尼治疗既往 ALK 阳性晚期 NSCLC：来自中国的 2 期研究的主要疗效和安全性。
J Thorac Oncol. 2022 Jun;17(6):816-826. doi: 10.1016/j.jtho.2022.02.014. Epub 2022 Mar 17.
6
Lorlatinib as a treatment for ALK-positive lung cancer.洛拉替尼治疗间变性淋巴瘤激酶阳性肺癌。
Future Oncol. 2022 Aug;18(24):2745-2766. doi: 10.2217/fon-2022-0184. Epub 2022 Jul 5.
7
First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.一线使用劳拉替尼治疗晚期ALK阳性非小细胞肺癌。
Lancet Respir Med. 2023 Apr;11(4):302-304. doi: 10.1016/S2213-2600(22)00488-X. Epub 2022 Dec 16.
8
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.劳拉替尼、阿来替尼和布加替尼在初治/未治疗的ALK阳性晚期非小细胞肺癌中的比较：一项系统评价和网状Meta分析
J Chemother. 2022 Apr;34(2):87-96. doi: 10.1080/1120009X.2021.1937782. Epub 2021 Jun 17.
9
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.晚期间变性淋巴瘤激酶阳性非小细胞肺癌中洛拉替尼的耐药突变与疗效。
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.
10
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.洛拉替尼在既往治疗的 ALK 阳性非小细胞肺癌患者中的脑渗透：CNS 和非 CNS 进展的累积发生率与洛拉替尼相关。
Target Oncol. 2020 Feb;15(1):55-65. doi: 10.1007/s11523-020-00702-4.